Hailong Li1, Jiasi Li2, Xiya Yu3, Huiwen Zheng2, Xu Sun2, Yue Lu2, Yanbo Zhang4, Chunbo Li5, Xiaoying Bi6. 1. Department of Neurology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, China; Department of Rehabilitation, Sanatorium of Air Force, 15 Yanggong Causeway, Hangzhou, China. 2. Department of Neurology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, China. 3. Department of Anesthesiology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, China. 4. Department of Psychiatry, College of Medicine University of Saskatchewan Ellis Hall, Royal University Hospital, Saskatoon, SK, Canada. Electronic address: yanbo.zhang@usask.ca. 5. Shanghai Metal Health Center, Shanghai Jiao Tong University School of Medicine, 600 Wan Ping Nan Road, Shanghai, China. Electronic address: chunbo_li@163.com. 6. Department of Neurology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, China. Electronic address: bxy616@sina.com.
Abstract
BACKGROUND: Numerous studies report that cancer prevalence in patients with schizophrenia might be different from the general population, but findings remain controversial. AIM: Our updated meta-analysis of cohort studies aims to analyze the data from cohort studies concerning the incidence risk of overall cancer and some site-specific cancers in patients with schizophrenia. METHOD: We performed a systemic search through electronic databases. Cohort studies evaluating and describing the cancer incidence among patients with schizophrenia were included. Pooled risk ratios (RRs) were calculated for assessing the incidence risk of cancer. RESULTS: There were 16 cohort studies included in this meta-analysis, which combined a total of 480,356 participants with schizophrenia and 41,999 cases of cancer. Results showed that there was a slight significant decreased overall risk ratio of cancer incidence among patients with schizophrenia (RR=0.90, 95% CI 0.81-0.99). When stratified by cancer site and gender, there were significant decreased incidence risk rates of colorectal cancer (RR=0.82, 95% CI 0.69-0.98) and prostate cancer (RR=0.55, 95% CI 0.42-0.71) in those patients, moreover, the incidence rate of colorectal cancer decreased significantly in male patients (RR=0.89, 95% CI 0.81-0.98), and the incidence rate of lung cancer increased significantly in female patients (RR=1.12, 95% CI 1.01-1.25). CONCLUSIONS: The incidence risk of some cancers was reduced in patients with schizophrenia. Gender and type of cancer were two important confounding factors contributed to the heterogeneity that required adjustment in our cancer incidence meta-analysis.
BACKGROUND: Numerous studies report that cancer prevalence in patients with schizophrenia might be different from the general population, but findings remain controversial. AIM: Our updated meta-analysis of cohort studies aims to analyze the data from cohort studies concerning the incidence risk of overall cancer and some site-specific cancers in patients with schizophrenia. METHOD: We performed a systemic search through electronic databases. Cohort studies evaluating and describing the cancer incidence among patients with schizophrenia were included. Pooled risk ratios (RRs) were calculated for assessing the incidence risk of cancer. RESULTS: There were 16 cohort studies included in this meta-analysis, which combined a total of 480,356 participants with schizophrenia and 41,999 cases of cancer. Results showed that there was a slight significant decreased overall risk ratio of cancer incidence among patients with schizophrenia (RR=0.90, 95% CI 0.81-0.99). When stratified by cancer site and gender, there were significant decreased incidence risk rates of colorectal cancer (RR=0.82, 95% CI 0.69-0.98) and prostate cancer (RR=0.55, 95% CI 0.42-0.71) in those patients, moreover, the incidence rate of colorectal cancer decreased significantly in male patients (RR=0.89, 95% CI 0.81-0.98), and the incidence rate of lung cancer increased significantly in female patients (RR=1.12, 95% CI 1.01-1.25). CONCLUSIONS: The incidence risk of some cancers was reduced in patients with schizophrenia. Gender and type of cancer were two important confounding factors contributed to the heterogeneity that required adjustment in our cancer incidence meta-analysis.
Authors: Riyue Bao; Anita Ng; Mark Sasaki; Myvizhi Esai Selvan; Alyna Katti; Hyesan Lee; Lei Huang; Andrew D Skol; Cinzia Lavarino; Hector Salvador; Robert J Klein; Zeynep H Gümüş; Jaume Mora; Kenan Onel Journal: Cancer Prev Res (Phila) Date: 2021-01-08